Malignant Anal Neoplasm — Trials

Malignant Anal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 68
Recruiting: 34
Ph III recruiting: 2
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.1%
Trials / 1,000 deaths: 42.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 1–32 of 32 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02314169	Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer	active not recruiting	Phase 2	143	National Cancer Institute (NCI)NIH	2	Sep 22, 2026	clinicaltrials
NCT07775209	Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma(SSIBLING)	enrolling by invitation	Phase 2	24	University of Vermont Medical CenterOTHER